Effective April 8, 2025, the company's prospectus supplement dated March 14, 2025, and the amended and restated prospectus supplement dated March 26, 2025, to the short form base shelf prospectus dated Nov. 28, 2024, were filed with and accepted by the TSX Venture Exchange.

The exchange has been advised that closing occurred on April 8, 2025, for gross proceeds of $3.2-million (U.S.)

Agent:  Research Capital Corp.

Offering:  65,435,521 common share units of the company (Each unit consists of one common share in the capital of the company and one share purchase warrant.)

Warrants:  Each warrant entitles the holder thereof to purchase one share at an exercise price of nine cents per share at any time until April 8, 2028.

Unit price:  seven cents per unit

Agent's commission:cash payment of $200,000, equal to 6 per cent of the gross proceeds of the offering (reduced to 2 per cent in respect of subscribers on the company's president's list); 3,030,693 non-transferable compensation warrants issued to the agent, entitling the agent to exercise each compensation warrant into one share at a price of seven cents per share at any time prior to April 8, 2028  

Overallotment option:  The company has granted to the agent an option to purchase additional units of up to 15 per cent of the offering for up to 30 days after closing. Any additional units sold as part of the overallotment is subject to exchange approval.

Please refer to the company's news releases dated March 12, 2025, March 25, 2025, and April 8, 2025, for further details.